Efficacy and Tolerance Study on the Use of the In-exsufflator in the Hospitalized Elderly
Launched by UNIVERSITY HOSPITAL, CLERMONT-FERRAND · Oct 11, 2021
Trial Information
Current as of June 04, 2025
Completed
Keywords
ClinConnect Summary
Background: One of the most frequent reasons for hospital admission of older adults are respiratory disorders. Physiological aging processes decrease respiratory muscle strength and can reduce the efficacity of cough. The mechanical in-exsufflator (MI-E) is a medical device used to help coughing. Studies have shown positive results in helping airway clearance in children and adults with neuromuscular pathologies however there is lack of evidence in older populations. This study's aim is to evaluate the feasibility of the MI-E in older adults. The hypothesis is that the use of MI-E in older ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patient hospitalize in Intensive Care Unit or Pulmonary Unit,
- • having airway clearance problem associated with mucus hypersecretion,
- • peak expiratory flow (PEF) \<280 l/min,
- • medical indication for respiratory physical therapy.
- Exclusion Criteria:
- • contraindication to use of MI-E device (ex. bronchospasm, immediate follow-up to surgery of airway system, chest or abdominal region, untreated pneumothorax, hemodynamic failure, etc.),
- • refuse to participate,
- • pregnant,
- • breastfeeding,
- • insufficient cognitive status.
About University Hospital, Clermont Ferrand
The University Hospital of Clermont-Ferrand is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. Renowned for its multidisciplinary approach, the hospital integrates cutting-edge scientific inquiry with patient care, fostering an environment that promotes collaboration among healthcare professionals, researchers, and academic partners. With a strong commitment to improving patient outcomes, the institution actively engages in a wide array of clinical studies, ranging from early-phase trials to large-scale interventions, aimed at addressing critical health challenges and enhancing treatment modalities. Its state-of-the-art facilities and expertise make it a pivotal contributor to clinical research in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Clermont Ferrand, , France
Patients applied
Trial Officials
Claire Estenne
Principal Investigator
University Hospital, Clermont-Ferrand
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials